FDA Class II Recall: Amerisource Health Services' Sucralfate Tablets Adulterated Post-Chapter 11 Filing
Amerisource Health Services LLC initiated a Class II recall of 27,868 blister packs of Sucralfate Tablets, USP 1 gram, distributed nationwide. This action stems from the firm's Chapter 11 bankruptcy filing on September 30, 2024, which compromised its ability to maintain CGMP standards, rendering the product adulterated. Procurement and regulatory teams must act swiftly to mitigate supply chain disruption and ensure compliance.
FDA Initiates Class II Recall for Amerisource Health Services' Sucralfate Due to Bankruptcy-Induced CGMP Deviations
The U.S. Food and Drug Administration (FDA) has announced a Class II recall, D-0027-2026, for Sucralfate Tablets, USP 1 gram, manufactured and distributed by American Health Packaging, with Amerisource Health Services LLC identified as the recalling firm. This critical action, initiated on October 9, 2025, directly results from Amerisource Health Services LLC filing for Chapter 11 bankruptcy on September 30, 2024. The bankruptcy filing has fundamentally compromised the firm's capacity to monitor its quality program, consequently preventing it from assuring that its products meet the requisite identity, strength, quality, and purity characteristics. This failure to uphold Current Good Manufacturing Practice (CGMP) standards renders the affected Sucralfate Tablets adulterated under FDA regulations. For procurement directors and regulatory affairs heads, this means an immediate and significant disruption to the supply of a critical oral prescription drug (ANDA074415). The inability of a supplier to maintain quality oversight due to financial distress presents a severe risk, necessitating urgent review of all inventory sourced from Amerisource Health Services LLC and a thorough assessment of potential regulatory non-compliance for any downstream products.
Amerisource Health Services' Financial Distress and Quality Program Collapse: Product Specifics
The recall specifically targets 27,868 blister packs of Sucralfate Tablets, USP 1 gram, distributed nationwide within the United States. These include Lot #: 1017392 with an expiration date of January 31, 2026, and Lot #: 1017415 with an expiration date of December 31, 2025. The product, identified by NDC 60687-695-01 (Carton NDC 60687-695-11 - Unit Dose), is a human prescription drug classified as an Aluminum Complex [EPC] and Organometallic Compound [CS], widely used for various gastrointestinal conditions. The recalling firm, Amerisource Health Services LLC, operates from Columbus, Ohio, United States. The core issue is not a specific manufacturing defect but a systemic breakdown of the quality assurance infrastructure, directly attributable to the firm's Chapter 11 bankruptcy. This scenario highlights a critical vulnerability: a supplier's financial health is inextricably linked to its ability to maintain regulatory compliance and product quality. For business development executives, this event signals a market void for Sucralfate, potentially creating opportunities for competitors. For supply chain VPs, it underscores the necessity of integrating financial risk assessments into supplier qualification processes, beyond traditional quality audits.
Immediate Supply Chain Disruption for Sucralfate Formulators Across the US
The nationwide distribution pattern of the recalled Sucralfate Tablets, USP 1 gram, means that pharmaceutical companies, hospitals, and pharmacies across the United States are directly impacted. Procurement directors must immediately identify and quarantine all affected lots (1017392 and 1017415) from Amerisource Health Services LLC to prevent further distribution of adulterated product. The recall of 27,868 blister packs represents a tangible supply gap that requires urgent mitigation. This situation creates significant operational challenges, as securing alternative sources for a prescription drug, especially one with a specific ANDA (ANDA074415), involves stringent qualification and regulatory approval processes. Regulatory affairs heads must assess the implications of using or having distributed an adulterated product, potentially triggering internal investigations and reporting obligations. The commercial impact extends beyond immediate product availability, potentially affecting patient treatment continuity and requiring communication strategies to manage stakeholder concerns. This event serves as a stark reminder that supplier financial stability is a critical component of supply chain resilience, directly influencing product quality and market availability.
Strategic Sourcing Challenges Amidst Limited Alternative Options for Sucralfate
The absence of readily available alternative suppliers in the current intelligence landscape for Sucralfate Tablets, USP 1 gram, exacerbates the supply chain challenges posed by this recall. Procurement teams are now under immense pressure to identify and qualify new sources for this critical molecule. The typical qualification timeline for a new pharmaceutical supplier, encompassing vendor audits, analytical method transfers, stability studies, and regulatory filings, can range from 6 to 18 months. This extended period highlights the inherent risks of single-source dependency, especially when a supplier faces financial distress leading to quality program collapse. Supply chain VPs must prioritize the development of robust multi-sourcing strategies and contingency plans for all critical raw materials and finished dosage forms. The current market dynamics suggest potential for short-term price volatility and extended lead times as demand shifts to a potentially constrained pool of qualified manufacturers. Business development executives should view this as an opportunity to engage with potential new suppliers or expand existing relationships to fill the emerging market gap for Sucralfate.
Heightened Regulatory Scrutiny and Industry-Wide Compliance Imperatives
This recall by Amerisource Health Services LLC underscores a broader trend of heightened regulatory scrutiny by the FDA, where financial instability is increasingly recognized as a direct precursor to quality system failures. Recent parallel events reinforce this environment: the FDA's Class II recall of Essential Wellness Pharma's Progesterone Injection in June 2026 due to sterility assurance failures, and the FDA hearing concerning Amgen's Tavneos market future, also in June 2026, highlighting the agency's focus on independent data review and market access. These incidents collectively signal a zero-tolerance approach to quality deviations and a proactive stance on risks that could compromise product integrity. For regulatory affairs heads, this means that due diligence on suppliers must extend beyond traditional quality audits to include financial health indicators and robust risk management frameworks. The FDA's consistent enforcement actions across various therapeutic areas demonstrate a clear expectation for pharmaceutical companies to maintain unwavering control over their quality programs, irrespective of internal corporate challenges. This necessitates a comprehensive, proactive approach to compliance that anticipates and mitigates potential vulnerabilities.
Navigating the Post-Recall Landscape: Mitigation and Future-Proofing Supply Chains
With the recall status listed as 'Ongoing,' the immediate priority for affected companies is to manage the current disruption and implement strategies to prevent future occurrences. Procurement directors must ensure complete removal of the recalled lots (1017392, 1017415) from their supply chain and secure interim supplies to maintain patient access to Sucralfate. This may involve expedited qualification processes for new vendors, though regulatory hurdles remain. Regulatory affairs teams need to document all actions taken in response to the recall and prepare for potential inquiries or audits from the FDA regarding their handling of adulterated products. Long-term, this event serves as a critical case study for supply chain VPs to re-evaluate their risk matrices, incorporating robust financial health assessments and multi-sourcing strategies as standard practice. The incident highlights that operational resilience is not solely about logistics but also about the financial viability and quality commitment of every link in the supply chain. Proactive investment in supplier diversification and continuous monitoring of vendor performance, including financial indicators, is paramount to future-proof supply chains against similar unforeseen disruptions.